Free Trial

Medexus Pharmaceuticals Q4 2023 Earnings Report

Medexus Pharmaceuticals logo
C$3.85 -0.14 (-3.51%)
As of 01/31/2025 03:59 PM Eastern

Medexus Pharmaceuticals EPS Results

Actual EPS
C$0.41
Consensus EPS
-C$0.07
Beat/Miss
Beat by +C$0.48
One Year Ago EPS
N/A

Medexus Pharmaceuticals Revenue Results

Actual Revenue
$38.72 million
Expected Revenue
$38.17 million
Beat/Miss
Beat by +$550.00 thousand
YoY Revenue Growth
N/A

Medexus Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Medexus Pharmaceuticals Earnings Headlines

Canadian Investment Regulatory Organization Trading Halt - MDP
Canadian Investment Regulatory Organization Trade Resumption - MDP
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. You see, I’ve recently uncovered a secret financial plot unfolding in Washington DC…
Bloom Burton Issues Optimistic Forecast for TSE:MDP Earnings
Bloom Burton Issues Pessimistic Outlook for TSE:MDP Earnings
Leede Financial Issues Positive Outlook for TSE:MDP Earnings
See More Medexus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medexus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medexus Pharmaceuticals and other key companies, straight to your email.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals (TSE:MDP) operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

View Medexus Pharmaceuticals Profile

More Earnings Resources from MarketBeat